Bevacizumab ELISA Kit

Details for Product No. ABIN1540255, Supplier: Log in to see
Antigen
Reactivity
Human
Alternatives
Kits with alternative reactivity to:
5
1
1
1
Method Type
Sandwich ELISA
Detection Range
30 ng/mL - 1000 ng/mL
Minimum Detection Limit
30 ng/mL
Application
ELISA
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Purpose The kit is a sandwich assay for the quantitative determination of bevacizumab in serum and plasma samples.
Brand SHIKARI®
Sample Type Plasma (EDTA), Plasma (heparin), Serum
Analytical Method Quantitative
Detection Method Colorimetric
Cross-Reactivity (Details) There is no cross reaction with native serum immunoglobulins.
Components 96 well plate, polyclonal antibody, standard,High and Low controls, wash buffer, assay buffer, TMB substrate, conjugate, stop buffer, Adhesive film
Material not included 1. Micropipettes (< 3 % CV) and tips to deliver 5-1000 μL.
2. Calibrated measures.
3. Tubes (1 mL) for sample dilution.
4. Wash bottle, automated or semi-automated microtiter plate washing system.
5. Microtiter plate reader capable of reading absorbance at 450/650 nm.
6. Bidistilled or deionised water, paper towels, pipette tips and timer.
Antigen
Target Type Antibody
Background Bevacizumab (Avastin®) is a recombinant human IgG1:k monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. In 1997, the humanization of the murine anti-VEGF Mab A.4.6.1. was reported. Like its murine counterpart, bevacizumab binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, but not mouse or rat VEGF. However, bevacizumab was observed to inhibit the growth of human tumor cell lines in nude mice. In addition, studies have demonstrated that bevacizumab, in combination with chemotherapy, resulted in increased survival in patients with previously untreated metastatic colorectal cancer relative to chemotherapy alone, leading to FDA approval of the first anti-angiogenic agent.
Application Notes Target: VEGF
Estimates biological levels in human, mouse, rat and monkey serum or plasma samples.
Comment

Free drug

Sample Volume 5 μL
Assay Time 1 h
Plate Pre-coated
Protocol Solid phase enzyme-linked immunosorbent assay (ELISA) based on the double antigen assay principle. Diluted standards and samples (serum or plasma) are incubated in the microtitre plate coated with human vascular endothelial growth factor (VEGF). After incubation, the wells are washed. A biotin conjugated human VEGF is added and binds to bevacizumab (Avastin®) captured by the reactant on the surface of the wells. Following incubation, wells are washed and then HRP conjugated probe (HRP) is added. After incubation, the wells are washed and the bound enzymatic activity is detected by addition of chromogen- substrate. The colour developed is proportional to the amount of bevacizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Assay Precision Intra-assay CV: <15% for bevacizumab range 30-1000 ng/mL.
Inter-assay CV: <15% for bevacizumab range 30-1000 ng/mL.
Restrictions For Research Use only
Buffer < 0.1 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Storage 4 °C
Storage Comment The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The strips of microtiter plate is stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.
Expiry Date 12 months
Supplier Images
ELISA image for Bevacizumab ELISA Kit (ABIN1540255) Typical Calibration Curve
ELISA image for Bevacizumab ELISA Kit (ABIN1540255) Bevacizumab ELISA Kit (Image 2)
ELISA image for Bevacizumab ELISA Kit (ABIN1540255) Bevacizumab ELISA Kit (Image 3)
Product cited in: Luis de Redín, Boiero, Martínez-Ohárriz, Agüeros, Ramos, Peñuelas, Allemandi, Llabot, Irache: "Human serum albumin nanoparticles for ocular delivery of bevacizumab." in: International journal of pharmaceutics, Vol. 541, Issue 1-2, pp. 214-223, 2018 (PubMed).

Gojo, Sauermann, Knaack, Slavc, Peyrl: "Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies." in: Drugs in R&D, Vol. 17, Issue 3, pp. 469-474, 2018 (PubMed).

Gregoritza, Abstiens, Graf, Goepferich: "Fabrication of antibody-loaded microgels using microfluidics and thiol-ene photoclick chemistry." in: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V, Vol. 127, pp. 194-203, 2018 (PubMed).

Chen, Yang, Luo, Yu: "Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus." in: Frontiers in plant science, Vol. 7, pp. 1156, 2016 (PubMed).

Van Bergen, Vandewalle, Moons, Stalmans: "Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery." in: Acta ophthalmologica, 2015 (PubMed).

Background publications Ferrara, Hillan, Novotny: "Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy." in: Biochemical and biophysical research communications, Vol. 333, Issue 2, pp. 328-35, 2005 (PubMed).

Ferrara, Hillan, Gerber, Novotny: "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer." in: Nature reviews. Drug discovery, Vol. 3, Issue 5, pp. 391-400, 2004 (PubMed).

Hurwitz, Fehrenbacher, Novotny, Cartwright, Hainsworth, Heim, Berlin, Baron, Griffing, Holmgren, Ferrara, Fyfe, Rogers, Ross, Kabbinavar: "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer." in: The New England journal of medicine, Vol. 350, Issue 23, pp. 2335-42, 2004 (PubMed).

Yang, Haworth, Sherry, Hwu, Schwartzentruber, Topalian, Steinberg, Chen, Rosenberg: "A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer." in: The New England journal of medicine, Vol. 349, Issue 5, pp. 427-34, 2003 (PubMed).

Kabbinavar, Hurwitz, Fehrenbacher, Meropol, Novotny, Lieberman, Griffing, Bergsland: "Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 1, pp. 60-5, 2002 (PubMed).

Gordon, Margolin, Talpaz, Sledge, Holmgren, Benjamin, Stalter, Shak, Adelman: "Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 19, Issue 3, pp. 843-50, 2001 (PubMed).

Ryan, Eppler, Hagler, Bruner, Thomford, Hall, Shopp, ONeill: "Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody." in: Toxicologic pathology, Vol. 27, Issue 1, pp. 78-86, 1999 (PubMed).

Presta, Chen, OConnor, Chisholm, Meng, Krummen, Winkler, Ferrara: "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders." in: Cancer research, Vol. 57, Issue 20, pp. 4593-9, 1997 (PubMed).

Did you look for something else?